PTE Ltd. | Date: 2016-07-11
A respiratory therapy apparatus includes components operable to simultaneously provide a High Frequency Chest Wall Oscillation (HFCWO) therapy and a Mechanical Insufflation/Exsufflation (MIE) therapy to a patient. The respiratory therapy apparatus includes a controller that controls a synchronization of the HFCWO therapy and the MIE therapy to provide respiratory therapy to the patient to effectively clear mucous or induce deep sputum from the lungs of patient.
News Article | December 28, 2016
MEDFORD, Mass.--(BUSINESS WIRE)--Today, Ascendance Biotechnology, Inc. (“Ascendance”), a leader in the commercialization of in vitro cell-based products and stem cell-related laboratory products, announced the execution of an Agreement with GE Healthcare (NYSE:GE) providing Ascendance a right to manufacture, market and sell the GE Healthcare Cytiva® brand of human stem cell-derived heart muscle cells (“cardiomyocytes”) used for evaluating potential cardiotoxicity. The Cytiva® product joins the first Ascendance stem cell-derived product, VascuNetTM, which is used for analyzing the capability of cancer drug candidates to inhibit the formation of blood vessels (angiogenesis), and which is also being evaluated as a tool for understanding the toxicologic effects of drug candidates on the cells lining the walls of blood vessels (endothelial cells). Existing Ascendance HepatoPac® and HepatoMune® products, which contain liver cells (hepatocytes), and which are designed for in vitro metabolite analysis, and toxicology and efficacy screening, are already helping to address inefficiencies in the development of pharmaceuticals, agro-chemicals and other products that may contain new chemical entities. The addition of the Cytiva® cardiomyocytes to the Ascendance product line is expected to further solidify the Company’s leadership position in the in vitro toxicology testing market, which may reach more than $17 billion by 2018 according to the Market and Markets research and consulting firm. “The execution of this Agreement represents another important step in the broadening of current Ascendance product lines,” stated Dr. Vincent Zurawski, Ascendance chief executive officer. Dr. Zurawski added, “We are delighted to report on the establishment of this important business relationship, which follows the completion of the arrangement between Hepregen Corporation and the ESI BIO division of BioTime, Inc. (NYSE MKT: BTX) that established the foundational assets of Ascendance. We are confident that continuing to establish important business partnerships will strengthen our ability to accelerate the Company’s leadership position in a rapidly growing cell biology market, while simultaneously increasing Company value for Ascendance stakeholders.” Jeffrey Janus, President of Ascendance, also commented, “The execution of this Agreement with a company as prestigious as GE Healthcare helps to validate our approach to new product development and also to strengthen the breadth of our global footprint. The continued expansion of the Company’s offerings beyond liver cell-based products to include both products and services based on multiple cell types, is expected to augment revenue growth for Ascendance, which is currently driven primarily by our line of HepatoPac® and HepatoMune® micro-patterned co-culture products.” Ascendance Biotechnology, Inc. (“Ascendance”) is a leader in innovating unique and proprietary bioengineered in vitro assay platforms and laboratory products for use in environmental testing, preventive care, and product development in the pharmaceutical and biopharmaceutical, diagnostic, cosmetics, and chemical industries. The Company’s application-directed micro-liver and micropatterned co-culture, cell-based assay kits are intended to drive a paradigm shift in drug development. The utility of the Company’s human, rat, monkey, dog, and multi-species/multi-donor HepatoPac® and HepatoMune® products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Ascendance was founded as a successor to Hepregen Corporation (“Hepregen”) and the ESI BIO Division of BioTime, Inc. (“BioTime”). Ascendance develops its own proprietary intellectual property and has also licensed technology from the Massachusetts Institute of Technology (“MIT”), Colorado State University, BioTime, and also ES Cell International PTE Ltd. (“ESI”) and ReCyte Therapeutics, Inc., both wholly owned subsidiaries of BioTime. This press release may contain forward-looking statements. Such forward-looking statements reflect Ascendance expectations about future operating results, performance and opportunities that involve substantial risk and uncertainties. These statements include but are not limited to statements regarding the performance and results of the company’s HepatoPac® and other kits. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Ascendance Biotechnology, Inc. or the management of either company are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company, and are subject to a number of risks, uncertainties and other factors that could cause the Company’s actual results, performance, prospects and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Pte. Ltd. and Ho | Date: 2013-10-02
A torque flywheel device includes a frame unit (1) and a wheel unit (2) mounted on the frame unit. The frame unit includes a support frame (10), a first track (12), a second track (13) and a third track (15). The wheel unit includes a shaft (22), a flywheel (20), a plurality of connecting bars (23), multiple support ears (24), multiple swinging weights (25), multiple first driving arms (26), multiple second driving arms (27), and multiple rollers (29). Thus, each of the rollers on the respective first driving arm and the respective second driving arm is movable to abut the third track and is movable to abut the first track and the second track so as to pivot the respective first driving arm and the respective second driving arm and to pivot the respective swinging weight.
Ohio State Innovation Foundation and Pte. Ltd. | Date: 2014-10-14
Disclosed herein are methods of repairing ear canal tissue defects by administering non-basic fibroblast growth factor (FGF) to the ear canal tissue defect. Also disclosed are delivery devices to administer said non-basic FGF.
D & P, Llc and Pte Ltd | Date: 2017-01-22
Pte Ltd. | Date: 2013-07-16
A splice sleeve having an elliptical or compound curve cross section for connecting overlapping end portions of reinforcing bars utilized in various types of structures in which steel reinforcing bars are utilized and it is desired to connect the overlapping end portions of the reinforcing bars. The splice sleeve is configured to receive the overlapped end portions of the reinforcing bars and then be filled with hardenable material to resist axial tension and compression exerted on the reinforcing bars. In one embodiment, both ends of the sleeve are provided with an inwardly directed lip to increase the splicing capacity of the sleeve and also to serve as a guide to position the rebars to a minimum of about 3 mm from the inside wall surface of the sleeve.
Pte. Ltd. | Date: 2016-01-07
Computer software and computer hardware for use in language localization, by means of language translation, subtitling, dubbing, closed captioning and teletext for feature films, television programs, videos and digital media in general; translation apparatus. Translation; language translation; translation services; providing translation services; translation and interpretation; provision of translation services; interpretation and translation services. Design and development of electronic language translation dictionaries and databases; programming of computer software for electronic language translation dictionaries and databases; providing temporary use of online, non-downloadable computer software for language translation.
Pte. Ltd. | Date: 2014-06-02
A security apparatus includes a mount and a sensor body with a socket recessed into the sensor body at a first angle from a functionality plane. The mount includes a stem and a base adapted to be affixed to a wall. The stem extends from the base at a second angle from horizontal. The functionality plane is set at an angle from horizontal equal to the first angle plus the second angle if the stem is inserted into the socket with the first side of the stem in close proximity to the first wall of the socket, and the functionality plane of the sensor body is set at an angle from horizontal equal to the first angle minus the second angle if the stem is inserted into the socket with the first side of the stem in close proximity to the second wall of the socket.
PTE. Ltd. | Date: 2016-08-17
A spectrometer (10) for measuring a spectral signature of an object comprises fringe generating optics (12) for use with a camera (65) and a processor. The fringe generating optics are formed of front optics (45) and birefringent optics (55). The front optics comprises a diffuser adapted to receive light from the object. The birefringent optics is adapted to receive light from the diffuser and to generate interference fringes. The camera is adapted to receive the interference fringes and the processor generates the spectral signature of the object. This spectrometer is an improved Fourier transform spectrometer suitable for use with digital cameras, such as cameras found in mobile devices.
Pte Ltd. | Date: 2014-07-07
A method is directed to visually displaying aggregate social media sentiment data potentially impacting the value of an organization. The organization, which purchases or sells a good, is selected and multiple search terms related to the organization are sent to a sentiment analysis system. Multiple scores are received from the sentiment analysis system. Each score is associated with corresponding ones of the search terms and is indicative of a sentiment level on a first set of one or more social networking services about the corresponding search term. An aggregate sentiment value is calculated based on the scores. The aggregate sentiment value is indicative of an aggregate sentiment about the corresponding search term on the first set of one or more social networking services. A first visual representation is displayed to indicate a relationship between a monitored characteristic of the selected organization and the aggregate sentiment.